Evidence map›Paper›PMID 32706142›Full record

ArticleCancer science2020

Effect of malignant-associated pleural effusion on endothelial viability, motility and angiogenesis in lung cancer.

Chih-Ying Changchien, Ying Chen, Hsin-Han Chang, Shan-Yueh Chang, Wen-Chiuan Tsai, Hao-Chung Tsai, Chieh-Yung Wang, Herng-Sheng Lee, Chen-Liang Tsai

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. OsimertinibTranslational lung cancer research · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Chih-Ying ChangchienDepartment of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Ying ChenDepartment of Biology and Anatomy, National Defense Medical Center, Taipei, Taiwan.ORCID https://orcid.org/0000-0001-6303-5858
Hsin-Han ChangDepartment of Biology and Anatomy, National Defense Medical Center, Taipei, Taiwan.
Shan-Yueh ChangDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Wen-Chiuan TsaiDepartment of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Hao-Chung TsaiDivision of Chest Medicine, Department of Internal Medicine, Tri-Service General Hospital Songshan Branch, National Defense Medical Center, Taipei, Taiwan.
Chieh-Yung WangDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Herng-Sheng LeeDepartment of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Chen-Liang TsaiDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.ORCID https://orcid.org/0000-0001-9783-5423
Tri-Service General Hospital · TWNational Defense Medical Center · TWKaohsiung Veterans General Hospital · TWTri-Service General Hospital Songshan Branch · TW

Funding

Ministry of Science and Technology, Taiwan MOST 107-2320-B-016-011-MY3Tri-Service General Hospital TSGH-C108-109
6 · The paper itself

Abstract

Malignant pleural effusion (MPE) and paramalignant pleural effusion (PPE) remain debilitating complications in lung cancer patients with poor prognosis and limited treatment options. The role of vascular endothelial cells has not been explored in the pleural environment of lung cancer. By integrating MPE and PPE as malignant-associated pleural fluid (MAPF), the current study aimed to evaluate the effect of MAPF on cell proliferation, migration and angiogenesis of HUVEC. First, increased capillaries were identified in the subpleural layer of lung adenocarcinoma. Compatible with pathological observations, the ubiquitous elevation of HUVEC survival was identified in MAPF culture regardless of the underlying cancer type, the driver gene mutation, prior treatments and evidence of malignant cells in pleural fluid. Moreover, MAPF enhanced HUVEC motility with the formation of lamellipodia and filopodia and focal adhesion complex. Tube formation assay revealed angiogenic behavior with the observation of sheet-like structures. HUVEC cultured with MAPF resulted in a significant increase in MAPK phosphorylation. Accompanied with VEGFR2 upregulation in MAPF culture, there was increased expressions of p-STAT3, HIF-1α and Nf-kB. VEGF/VEGFR2 blockade regressed endothelial migration and angiogenesis but not cell proliferation. Our data indicate the angiogenic activities of MAPF on vascular endothelial cells that revealed increased pleural capillaries in lung cancer. Targeting the VEGF/VEGFR2 pathway might modulate the angiogenic propensity of MAPF in future clinical investigations.

Indexed as

AgedCell Line, TumorCell MovementCell ProliferationCell SurvivalEndothelium, VascularFemaleHumansHuman Umbilical Vein Endothelial CellsHypoxia-Inducible Factor 1, alpha SubunitLung NeoplasmsMaleNeovascularization, PathologicNF-kappa BPleural EffusionPleural Effusion, MalignantHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitKDR protein, humanNF-kappa BSTAT3 protein, humanSTAT3 Transcription FactorVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2VEGFA protein, humanangiogenesislung cancermalignant pleural effusionvascular endotheliumVEGFR2

Identifiers

PMID32706142
PMCPMC7541005
OpenAlexW3044868814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.